



# Search results

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:348803 CAPLUS Full-text  
 DN 138:354008  
 TI Synthesis of diazabicycloalkanecarboxamides as caspase inhibitors  
 IN Robidoux, Andrea L. C.; Wilson, Jeffrey Douglas; Dieterich, Petra;  
 Storer, Neil; Leonardi, Stefania  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO U.S., 14 pp., Cont.-in-part of U.S. 6,201,118.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6559304	B1	20030506	US 2000-688301	20001013
	US 6201118	B1	20010313	US 1998-136339	19980819
PRAI	US 1998-136339	A2	19980819		
OS	CASREACT 138:354008; MARPAT 138:354008				
GI					



AB Diazabicycloalkanecarboxamides I [ $m = 0-2$ ;  $n = 0, 1$ ;  $X = \text{CH}, \text{N}$ ;  $R = \text{H}$ , aryl, acyl, (un)substituted alkyl,  $\text{CO}_2\text{H}$ ,  $\text{SO}_2\text{H}$ ,  $\text{CONH}_2$ ,  $\text{SO}_2\text{NH}_2$ ;  $R_1 = \text{OH}$ ,  $\text{CF}_3$ ,  $\text{COCO}_2\text{H}$ ,  $\text{CO}_2\text{H}$ , (un)substituted alkyl;  $R_2 = \text{CN}$ , (un)substituted  $\text{CH}:\text{CH}_2$ ,  $\text{CH}:\text{NOH}$ , alkyl, acyl,  $\text{COCONH}_2$ ] were prepared as known caspase inhibitors. Thus, the pyridazodiazepinecarboxamide II was prepared from  $\text{Br}(\text{CH}_2)_4\text{CO}_2\text{H}$  in 9 steps.


IT **192756-07-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of diazabicycloalkanecarboxamides as caspase inhibitors)

RN 192756-07-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:816645 CAPLUS Full-text  
 DN 135:344728  
 TI Asymmetric synthesis of piperazic acid and derivatives  
 IN Robidoux, Andrea; Serafini, Siro; Dieterich, Petra; Leonardi, Stephania;  
 Stibbard, John  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083458	A2	20011108	WO 2001-US13330	20010425
	WO 2001083458	A3	20020523		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1280780	A2	20030205	EP 2001-930747	20010425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003176691	A1	20030918	US 2002-168463	20020614
	US 6632942	B2	20031014		
PRAI	US 2000-202104P	P	20000504		
	WO 2001-US13330	W	20010425		
OS	CASREACT 135:344728; MARPAT 135:344728				
GI					




AB Piperazic acids I [R is H or a carboxy-protecting group; R1, R2 = H or anamino protecting group; R1 and R2 may be taken together to form a fused bicyclic or tricyclicamino protecting group (R1 = R2 ≠ H)] were prepared by treating R4O(CH2)3CH(OR4)CO2R (OR4 is a leaving group) with hydrazines R1NHNHR2 in the presence of a base and an organic solvent. Thus, treating a solution of CbzNHNHCbz (Cbz = PhCH2O2C) and (R)-tert-Bu 2,5-dimesylvalerate in DMF with Na2SO4 and TBAF and stirring the mixture at room temperature for 24 h afforded (S)-tert-Bu 1,2-bis(benzyloxycarbonyl)hexahydro-3-pyridazinecarboxylate.

IT **192756-07-3P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (asym. synthesis of piperazic acid and derivs.)

RN 192756-07-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:489403 CAPLUS Full-text

DN 135:92659

TI Preparation of carboxamide diazepin derivatives and their inhibition of cathepsin K, cathepsin B, and papain

IN Bhatnagar, Neerja; Mauger, Jacques

PA Aventis Pharma S.A., Fr.

SO PCT Int. Appl., 231 pp.


CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047930	A1	20010705	WO 2000-FR3622	20001221
	W:				
	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2802927	A1	20010629	FR 1999-16567	19991228
	FR 2802927	B1	20020301		
	EP 1246824	A1	20021009	EP 2000-990087	20001221
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000016845	A	20021015	BR 2000-16845	20001221
	JP 2003519152	T2	20030617	JP 2001-549400	20001221
	EE 200200362	A	20030815	EE 2002-362	20001221
	NO 2002003107	A	20020827	NO 2002-3107	20020627
	US 2003100550	A1	20030529	US 2002-168116	20020708
PRAI	FR 1999-16567	A	19991228		
	WO 2000-FR3622	W	20001221		
OS	MARPAT 135:92659				
GI					



AB The title compds. I [R1 = C(O), R5, SO2R5, C(O)NR6R5; R2 and R7 are such that either R7 represents a hydrogen atom and R2 is such that the group (a) represents the radical of a natural or nonnatural amino acid, or R2 and R7 form together a cycle with the nitrogen and carbon atom whereto they are bound; R3 = CH:N2 or CH2LR4, R4 represents in particular a linear or branched alkyl radical], inhibitors of cathepsin K, cathepsin B, and papain, were prepared E.g., 3-[9(S)-benzoylamino-6,10-dioxo-1,2,3,4,7,8,9,10-octahydro-6H-pyridazino[1,2-a][1,2]diazepine-1(S)-carboxamide]-5-methyl-1-benzoyloxyhexane-2-one was prepared

IT 348102-54-5P 348102-56-7P 348102-58-9P  
348102-60-3P 348102-62-5P 348102-64-7P  
348102-66-9P 348102-68-1P 348102-70-5P  
348102-72-7P 348102-74-9P 348102-94-3P

348102-96-5P 348102-98-7P 348103-00-4P  
 348103-02-6P 348103-04-8P 348103-06-0P  
 348103-08-2P 348103-10-6P 348103-12-8P  
 348103-14-0P 348103-16-2P 348103-18-4P  
 348103-20-8P 348103-22-0P 348103-24-2P  
 348103-26-4P 348103-28-6P 348103-30-0P  
 348103-32-2P 348103-34-4P 348103-36-6P  
 348103-38-8P 348103-40-2P 348103-42-4P  
 348103-44-6P 348103-46-8P 348103-48-0P  
 348103-50-4P 348103-52-6P 348103-54-8P  
 348103-56-0P 348103-58-2P 348103-59-3P  
 348103-61-7P 348103-63-9P 348103-65-1P  
 348103-67-3P 348103-69-5P 348103-71-9P  
 348103-76-4P 348103-78-6P 348103-80-0P  
 348103-82-2P 348103-84-4P 348103-86-6P  
 348103-88-8P 348103-90-2P 348103-92-4P  
 348103-94-6P 348103-96-8P 348103-98-0P  
 348104-01-8P 348104-03-0P 348104-05-2P  
 348104-07-4P 348104-09-6P 348104-11-0P  
 348104-13-2P 348104-15-4P 348104-17-6P  
 348104-19-8P 348104-21-2P 348104-23-4P  
 348104-25-6P 348104-27-8P 348104-29-0P  
 348104-32-5P 348104-34-7P 348104-36-9P  
 348104-38-1P 348104-40-5P 348104-42-7P  
 348104-45-0P 348104-47-2P 348104-49-4P  
 348104-51-8P 348104-53-0P 348104-55-2P  
 348104-57-4P 348104-59-6P 348104-61-0P  
 348104-63-2P 348104-64-3P 348104-65-4P  
 348104-66-5P 348104-68-7P 348104-70-1P  
 348104-72-3P 348104-74-5P 348104-76-7P  
 348104-78-9P 348104-80-3P 348104-82-5P  
 348104-84-7P 348104-86-9P 348104-88-1P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of carboxamide diazepam derivs. and their inhibition of  
 cathepsin K, cathepsin B, and papain)

RN 348102-54-5 CAPLUS

CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.




RN 348102-56-7 CAPLUS

CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-

2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-58-9 CAPLUS

CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-


2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-60-3 CAPLUS  
 CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-62-5 CAPLUS  
 CN Hexanoic acid, 4-[[[(1S,9S)-9-[[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-6-diazo-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348102-64-7 CAPLUS  
 CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348102-66-9 CAPLUS

CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348102-68-1 CAPLUS


CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-70-5 CAPLUS  
 CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-72-7 CAPLUS  
 CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-74-9 CAPLUS  
 CN Hexanoic acid, 6-diazo-4-[[[(1S,9S)-octahydro-9-[[[5-(3-isoxazolyl)-2-thienyl]sulfonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-94-3 CAPLUS  
 CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-96-5 CAPLUS  
 CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348102-98-7 CAPLUS  
 CN Hexanoic acid, 6-[[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-  
 9-  
 [(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-  
 a][1,2]diazepin-  
 1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 348103-00-4 CAPLUS  
 CN Hexanoic acid, 6-(benzoyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-  
 oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 348103-02-6 CAPLUS

CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.




RN 348103-04-8 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.




RN 348103-06-0 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX  
NAME)


Absolute stereochemistry.



RN 348103-08-2 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-10-6 CAPLUS

CN 1-Piperazinehexanoic acid, 4-[2-(diethylamino)ethyl]- $\gamma$ -[[[(1S,9S)-octahydro-9-[(2-methyl-1-oxopropyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-12-8 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-14-0 CAPLUS


CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348103-16-2 CAPLUS  
 CN Hexanoic acid, 6-[[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-  
 9-  
 [(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-  
 1-  
 yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 348103-18-4 CAPLUS  
 CN Hexanoic acid, 6-(benzoyloxy)-4-[[[(1S,9S)-octahydro-9-[(3-  
 methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 348103-20-8 CAPLUS

CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.




RN 348103-22-0 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.




RN 348103-24-2 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)


Absolute stereochemistry.



RN 348103-26-4 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-28-6 CAPLUS

CN 1-Piperazinehexanoic acid, 4-[2-(diethylamino)ethyl]- $\gamma$ -[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-30-0 CAPLUS

CN Hexanoic acid, 6-[(4-methoxyphenyl)thio]-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-32-2 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-(2-pyrimidinylthio)-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348103-34-4 CAPLUS

CN Benzoic acid, 3-(1-cyanoethyl)-, (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.




RN 348103-36-6 CAPLUS

CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)


Absolute stereochemistry.



RN 348103-38-8 CAPLUS

CN 1-Piperidinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-(phenylmethyl)-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-40-2 CAPLUS

CN 1-Piperidinehexanoic acid, 3-[(diethylamino)carbonyl]-γ-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-42-4 CAPLUS

CN Hexanoic acid, 6-(4-fluorophenoxy)-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-44-6 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)oxy]-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-46-8 CAPLUS


CN Hexanoic acid, 6-[2-(acetylamino)phenoxy]-4-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348103-48-0 CAPLUS  
 CN Hexanoic acid, 6-[4-[(diethylamino)carbonyl]-2-methoxyphenoxy]-4-  
 [[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-  
 pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl  
 ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348103-50-4 CAPLUS  
 CN Hexanoic acid, 4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-  
 dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-  
 [(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 348103-52-6 CAPLUS  
 CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-9-[(2-  
 furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-  
 a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-  
 (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-54-8 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-6-[[4-methoxyphenyl)methyl]thio]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-56-0 CAPLUS

CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-58-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-59-3 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 348103-61-7 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-63-9 CAPLUS

CN Pentanedioic acid, (3S)-3-[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-65-1 CAPLUS

CN 1-Piperidinehexanoic acid,  $\gamma$ -[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-(phenylmethyl)-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-67-3 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-9-[(2-furanylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-69-5 CAPLUS


CN Hexanoic acid, 6-[[[4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348103-71-9 CAPLUS  
 CN Hexanoic acid, 6-[(4-methoxyphenyl)thio]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 348103-76-4 CAPLUS  
 CN Hexanoic acid, 6-(benzoyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-78-6 CAPLUS

CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-80-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-82-2 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-84-4 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-86-6 CAPLUS

CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-88-8 CAPLUS

CN Hexanoic acid, 6-[2-(acetylamino)phenoxy]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-90-2 CAPLUS

CN Hexanoic acid, 6-[4-[(diethylamino)carbonyl]-2-methoxyphenoxy]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-92-4 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348103-94-6 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[[[2-naphthalenylsulfonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[[[1-phenyl-1H-tetrazol-5-yl]thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348103-96-8 CAPLUS

CN Hexanoic acid, 6-[[[(4S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 348103-98-0 CAPLUS

CN Hexanoic acid, 6-(benzyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-01-8 CAPLUS

CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.




RN 348104-03-0 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX


NAME)

Absolute stereochemistry.




RN 348104-05-2 CAPLUS  
 CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA  
 INDEX  
 NAME)

Absolute stereochemistry.



RN 348104-07-4 CAPLUS  
 CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA  
 INDEX  
 NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

—OMe

RN 348104-09-6 CAPLUS

CN Hexanoic acid, 6-[2-(acetylamino)phenoxy]-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-11-0 CAPLUS

CN Hexanoic acid, 6-[4-[(diethylamino)carbonyl]-2-methoxyphenoxy]-4-[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

—NEt<sub>2</sub>

RN 348104-13-2 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-9-[(2-naphthalenylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-15-4 CAPLUS


CN Hexanoic acid, 6-[[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-17-6 CAPLUS  
 CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA  
 INDEX  
 NAME)

Absolute stereochemistry.




RN 348104-19-8 CAPLUS  
 CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-[(4-morpholinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA  
 INDEX  
 NAME)

Absolute stereochemistry.




RN 348104-21-2 CAPLUS  
 CN Hexanoic acid, 4-[[[(1S,9S)-9-[[[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-6-[[[(4-methoxyphenyl)methyl]thio]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 348104-23-4 CAPLUS  
 CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-  
 [[(cyclohexylamino)carbonyl]amino]octahydro-6,10-dioxo-6H-  
 pyridazino[1,2-  
 a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl  
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-25-6 CAPLUS  
 CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-9-  
 [[(cyclohexylamino)carbonyl]am  
 ino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 348104-27-8 CAPLUS  
 CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-9-  
 [[(cyclohexylamino)carbonyl]am  
 ino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA  
 INDEX  
 NAME)

Absolute stereochemistry.



RN 348104-29-0 CAPLUS  
 CN Pentanedioic acid, (3S)-3-[[[(1S,9S)-9-  
 [[(cyclohexylamino)carbonyl]amino]o  
 ctahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-  
 2,6-dioxo-6-(2-propenyloxy)hexyl methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-32-5 CAPLUS

CN 1-Piperidinehexanoic acid,  $\gamma$ -[[[(1S,9S)-9-  
[[ (cyclohexylamino) carbonyl] amino] octahydro-6,10-dioxo-6H-  
pyridazino[1,2-  
a] [1,2] diazepin-1-yl] carbonyl] amino]- $\delta$ -oxo-4-(phenylmethyl)-,  
2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-34-7 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-9-  
[[ (cyclohexylamino) carbonyl] amino] octahydro-6,10-dioxo-6H-  
pyridazino[1,2-  
a] [1,2] diazepin-1-yl] carbonyl] amino]- $\delta$ -oxo-4-[2-oxo-2-(1-  
pyrrolidinyl)ethyl]-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-36-9 CAPLUS


CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-38-1 CAPLUS  
 CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 348104-40-5 CAPLUS  
 CN Hexanoic acid, 6-[[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-42-7 CAPLUS

CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)


Absolute stereochemistry.



RN 348104-45-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-47-2 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-49-4 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-51-8 CAPLUS

CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX  
NAME)


Absolute stereochemistry.



RN 348104-53-0 CAPLUS

CN 1-Piperidinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-(phenylmethyl)-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-55-2 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-57-4 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-59-6 CAPLUS


CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-61-0 CAPLUS  
 CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-  
 [[[[2-  
 (2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-  
 a][1,2]diazepin-1-  
 yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA  
 INDEX  
 NAME)

Absolute stereochemistry.



RN 348104-63-2 CAPLUS  
 CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-  
 [[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-  
 a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl  
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-64-3 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-65-4 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348104-66-5 CAPLUS

CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-  
[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-  
a][1,2]diazepin-1-yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)


Absolute stereochemistry.



RN 348104-68-7 CAPLUS

CN 1-Piperazinehexanoic acid,  $\gamma$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-6H-pyridazino[1,2-  
a][1,2]diazepin-1-yl]carbonyl]amino]- $\delta$ -oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-,  
2-propenyl ester, ( $\gamma$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-70-1 CAPLUS

CN Hexanoic acid, 4-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-6-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-72-3 CAPLUS

CN Hexanoic acid, 6-(2-benzothiazolylthio)-4-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-74-5 CAPLUS

CN Hexanoic acid, 6-[[[(4-methoxyphenyl)methyl]thio]-4-[[[(1S,9S)-octahydro-9-  
9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 348104-76-7 CAPLUS

CN 4-Pyridinecarboxylic acid, (3S)-3-[[[(1S,9S)-octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA  
INDEX  
NAME)

Absolute stereochemistry.




RN 348104-78-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.




RN 348104-80-3 CAPLUS

CN Hexanoic acid, 6-(acetyloxy)-4-[[[(1S,9S)-octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-5-oxo-, 2-propenyl ester, (4S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.




RN 348104-82-5 CAPLUS

CN 3-Thiopheneacetic acid, (3S)-3-[[[(1S,9S)-octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX  
NAME)

Absolute stereochemistry.




RN 348104-84-7 CAPLUS

CN Pentanedioic acid, methyl (3S)-3-[[[(1S,9S)-octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2,6-dioxo-6-(2-propenyloxy)hexyl ester (9CI) (CA

INDEX  
NAME)


Absolute stereochemistry.



RN 348104-86-9 CAPLUS

CN 1-Piperidinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-δ-oxo-4-(phenylmethyl)-, 2-propenyl ester,  
(γS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348104-88-1 CAPLUS

CN 1-Piperazinehexanoic acid, γ-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-δ-oxo-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, 2-propenyl ester, (γS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:144862 CAPLUS Full-text  
 DN 132:180588  
 TI Preparation of (annelated)piperazic acids as caspase inhibitor intermediates  
 IN Robidoux, Andrea L. C.; Wilson, Jeffrey Douglas; Dieterich, Petra; Storer, Neil; Leonardi, Stefania  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 45 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010979	A1	20000302	WO 1999-US19080	19990819
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6201118	B1	20010313	US 1998-136339	19980819
	US 6177565	B1	20010123	US 1999-235894	19990122
	AU 9956840	A1	20000314	AU 1999-56840	19990819
	EP 1104409	A1	20010606	EP 1999-943814	19990819
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2001031862	A1	20011018	US 2001-789049	20010220
PRAI	US 1998-136339	A	19980819		
	US 1999-235894	A	19990122		
	WO 1999-US19080	W	19990819		
OS	CASREACT 132:180588; MARPAT 132:180588				
GI					



AB Title compds., e.g., I (R2 = H, alkyl, aryl, etc.; Z = bond or CH2) [II; R = H, R1 = Z1CO2H, Z1 = (un)substituted (oxo)alkylene] were prepared and cyclized to II (RR1 = COZ1). Thus, Br(CH2)3CHBrCO2CMe3 (preparation given) was cyclocondensed with (PhCH2O2CNH)2 to give I (R2 = CMe3, Z = CH2) (II; R = R1 = CO2CH2Ph) which was deprotected and the product N-acylated with (S)-3-phthalimido-2,6-dioxopyran to give II [R = H, R1 = (S)-HO2CCHR3CH2CH2CO, R3 = phthalimido]. The latter was treated with

SOCl<sub>2</sub>/2,6-lutidine to give, after hydrazinolysis, II [RR1 = (S)-COCHNH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO].

IT 192756-07-3P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of (annelated)piperazic acids as caspase inhibitor intermediates)


RN 192756-07-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 7


THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:386128 CAPLUS Full-text  
 DN 131:144580  
 TI An efficient stereoselective synthesis of [3S(1S,9S)]-3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) inhibitor  
 AU Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R.  
 CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA  
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(11), 1587-1592  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 GI




AB The title compound (I) is a potent interleukin-1 $\beta$ -converting enzyme inhibitor. Recently, an efficient chiral synthesis of I was accomplished in our labs. The overall yield of this 18-step stereoselective synthesis was 9.8%.  
 IT **192755-43-4P 234752-71-7P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (stereoselective preparation of interleukin converting enzyme inhibitor)  
 RN 192755-43-4 CAPLUS  
 CN Butanoic acid, 3-[[[ (1S,9S) -9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234752-71-7 CAPLUS  
 CN Butanoic acid, 3-[[[ (1S) -9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 174799-23-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(stereoselective preparation of interleukin converting enzyme inhibitor)

RN 174799-23-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:136764 CAPLUS Full-text  
 DN 130:196957  
 TI Preparation of bicyclic peptide derivatives as interleukin-1 $\beta$   
 converting enzyme inhibitors  
 IN Batchelor, Mark James; Bebbington, David; Bemis, Guy W.; Fridman, Wolf  
 Herman; Gillespie, Roger John; Golec, Julian M. C.; Lauffer, David J.;  
 Livingston, David J.; Matharu, Saroop Singh; Mullican, Michael D.;  
 Murcko,  
 Mark A.; Murdoch, Robert; Zelle, Robert E.  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO U.S., 189 pp., Cont.-in-part of U.S. Ser. No. 575,641.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5874424	A	19990223	US 1996-598332	19960208
	US 6008217	A	19991228	US 1995-575641	19951220
	US 6204261	B1	20010320	US 1996-761483	19961206
	IN 182290	A	19990306	IN 1996-CA2188	19961218
	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	ZA 9610798	A	19970707	ZA 1996-10798	19961220
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9612258	A	19990713	BR 1996-12258	19961220
	CN 1229412	A	19990922	CN 1996-199828	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	JP 2003137896	A2	20030514	JP 2002-306094	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	US 6258948	B1	20010710	US 1999-400639	19990921
	US 6423840	B1	20020723	US 2001-773477	20010131
	AU 756253	B2	20030109	AU 2001-76122	20010928
	US 2003225269	A1	20031204	US 2002-58522	20020128
PRAI	US 1995-575641	A2	19951220		
	US 1996-598332	A2	19960208		
	US 1996-712878	A2	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	JP 1997-523098	A3	19961220		
	WO 1996-US20843	W	19961220		
	US 1999-400639	A3	19990921		

US 2001-773477 A3 20010131  
 OS MARPAT 130:196957  
 GI



AB Title compds. I [m = 1-2; R3 = CN, CHO, COCH2-T1-R11, COCH2F, C:NOR9, COAr2; R5 = COR10, CO2R9, CONR102, SO2R9, SO2NHR10, COCH2OR9, COCOR10, R9, H, COCO2R10, COCONR9R10; Y = O, H2; T1 = O, S, S(O), SO2; R9 = Ar3, (un)branched C1-6 alkyl optionally unsatd. and optionally substituted with Ar3; R10 = H, Ar3, C3-6 cycloalkyl, any group R9; R11 = Ar4, (CH2)1-3Ar4, H, COAr4; R15 = OH, OAr3, NHOH, (un)branched C1-6 alkoxy optionally unsatd. and optionally substituted with Ar3, CONH2, OR5, OH, OR9, CO2H; Ar2 = (un)substituted 2-oxazolyl, 2-benzoxazolyl, 2-thiazolyl, 2-benzothiazolyl; Ar3, Ar4 = optionally substituted, nitrogen-containing heteroarom. or heterocyclic group containing 1-3 rings] were prepared as inhibitors of interleukin-1 $\beta$  converting enzyme. Thus, bicyclic peptide derivative II was prepared and shown to have Ki = 13 nM in a UV-visible assay and IC50 = 11000 nM in a peripheral blood mononuclear cell (PBMC) assay.

IT 174799-23-6P 192754-08-8P 192754-09-9P  
 192755-43-4P

RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological


study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT  
 (Reactant or reagent); USES (Uses)

(preparation of bicyclic peptide derivs. as interleukin-1 $\beta$  converting  
 enzyme inhibitors)

RN 174799-23-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-  
 pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 192754-08-8 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[2,6-dichlorophenyl)methoxy]imino]-, 1,1-dimethylethyl ester, (3S)-(9CI)

(CA

INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 192754-09-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 192755-43-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174799-04-3P 174799-05-4P 174799-28-1P  
 175209-10-6P 175209-11-7P 175209-35-5P  
 175209-36-6P 175209-41-3P 175209-48-0P  
 175209-61-7P 175209-93-5P 192753-95-0P  
 192753-97-2P 192754-02-2P 192754-03-3P  
 192754-10-2P 192754-11-3P 192754-50-0P  
 192754-51-1P 192754-52-2P 192754-53-3P  
 192754-56-6P 192754-57-7P 192754-59-9P  
 192754-61-3P 192754-76-0P 192754-98-6P  
 192755-26-3P 192755-28-5P 192755-29-6P  
 192755-30-9P 192755-31-0P 192755-32-1P  
 192755-33-2P 192755-34-3P 192755-99-0P  
 192756-00-6P 192756-01-7P 192756-02-8P  
 192756-03-9P 192756-04-0P 192756-05-1P  
 192756-06-2P 192756-07-3P 192756-08-4P  
 192756-09-5P 192756-10-8P 192756-11-9P  
 192756-12-0P 192756-13-1P 192756-14-2P  
 192756-15-3P 192756-16-4P 192756-17-5P  
 192756-19-7P 192756-20-0P 192756-21-1P  
 192756-22-2P 192756-23-3P 192756-24-4P  
 192756-25-5P 192756-26-6P 192756-28-8P  
 192756-29-9P 192756-30-2P 192756-31-3P  
 192756-32-4P 192756-33-5P 192756-34-6P  
 192756-35-7P 192756-36-8P 192756-37-9P  
 192756-38-0P 192756-39-1P 192756-40-4P  
 192756-41-5P 192756-42-6P 192756-43-7P  
 192756-44-8P 192756-45-9P 192756-46-0P  
 192756-48-2P 192756-49-3P 192756-50-6P  
 192756-51-7P 192756-52-8P 192756-53-9P  
 192756-54-0P 192756-55-1P 192756-56-2P  
 192756-57-3P 192756-58-4P 192756-59-5P  
 192756-61-9P 192756-62-0P 192756-63-1P  
 192756-65-3P 192756-66-4P 192756-68-6P  
 192756-69-7P 192756-70-0P 192756-71-1P  
 192756-73-3P 192756-74-4P 192756-75-5P  
 192756-76-6P 192756-77-7P 192756-78-8P


192756-79-9P 192756-80-2P 192756-81-3P  
 192756-82-4P 192756-83-5P 192756-84-6P  
 192756-86-8P 192756-87-9P 192756-88-0P  
 192756-89-1P 192762-50-8P 220743-36-2P  
 220743-37-3P 220743-39-5P 220743-43-1P  
 220743-44-2P 220743-45-3P 220743-47-5P  
 220743-50-0P

RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of bicyclic peptide derivs. as interleukin-1 $\beta$  converting enzyme inhibitors)

RN 174799-04-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-05-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 174799-28-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 175209-35-5 CAPLUS

CN 2-Benzoxazolebutanoic acid, 7-methoxy- $\beta$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]- $\gamma$ -oxo-, ( $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy- $\beta$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]- $\gamma$ -oxo-, ( $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-41-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-48-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-61-7 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-93-5 CAPLUS

CN Pentanoic acid, 5-[[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 192753-95-0 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 192753-97-2 CAPLUS

CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-02-2 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 192754-03-3 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4R)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 192754-10-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[2,6-dichlorophenyl)methoxy]imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 192754-11-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 192754-50-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-51-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-52-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 192754-53-3 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-56-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-57-7 CAPLUS

CN 2-Benzoxazolebutanoic acid,  $\beta$ -[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro- $\gamma$ -oxo-, ( $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-59-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[[(2-chlorophenyl)methyl]thio]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-61-3 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-76-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-98-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,8S,9S)-9-(benzoylamino)octahydro-8-methyl-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-26-3 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-28-5 CAPLUS


CN Sulfonium, [(3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl][(2-chlorophenyl)methyl]methyl-, tetrafluoroborate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 192755-27-4

CMF C30 H34 Cl N4 O7 S

Absolute stereochemistry.




CM 2

CRN 14874-70-5

CMF B F4


CCI CCS



RN 192755-29-6 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-30-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-31-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-32-1 CAPLUS

CN Benzoic acid, 2,6-dimethyl-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-33-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-34-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-chloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-99-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-00-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-01-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-chlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-02-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-03-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-naphthalenylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-04-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[[1,1'-biphenyl]-4-yl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-05-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-thienylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-06-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(2-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-07-3 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-08-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(cyclopropylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-09-5 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(1,3-benzodioxol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-10-8 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-chlorobenzoyl)amino]octahydro-6,10-

dioxo-  
6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 192756-11-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3,4,5-trimethoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-12-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-13-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-14-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-15-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(ethylsulfonyl)amino]octahydro-6,10-dioxo-


6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-16-4 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-9-[[[1-ethyl-3-methyl-1H-pyrazol-5-yl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-17-5 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-9-[[[2,4-dimethyl-5-thiazolyl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-19-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[[6-hydroxy-2-naphthalenyl]carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-20-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(cyclohexylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-21-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(phenylsulfonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-22-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[dimethylamino]sulfonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-23-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-

a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-24-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[2-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-25-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-aminobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-26-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(1H-benzotriazol-5-yl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-


yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-28-8 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(1H-benzimidazol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-29-9 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-30-2 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-31-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-methoxy-2-quinolinyl]carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-32-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[6-quinolinyl]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-33-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[8-quinolinyl]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-34-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[[3-amino-2-naphthalenyl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-35-7 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-9-[[[4-(dimethylamino)-1-naphthalenyl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-36-8 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(thieno[2,3-b]thien-2-ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-37-9 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-phenoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-38-0 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-9-[(2,6-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-39-1 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1H-imidazol-2-ylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-40-4 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1,2,3-thiadiazol-5-ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-41-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(methylsulfonyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-42-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(acetylmethylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-43-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[1-(1-hydroxy-2-naphthalenyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-44-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[3-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-45-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-46-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-48-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-pyridinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-49-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-50-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-hydroxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,

(3S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-51-7 CAPLUS

CN Benzoic acid, 4-hydroxy-, 4-[[[(4S,7S)-4-[[[(1S)-2-carboxy-1-formylethyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-52-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-difluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-53-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-fluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-54-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-(methylsulfonyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-55-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluorobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-56-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-fluorobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)


(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-57-3 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-58-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-2-methylbenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-59-5 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(5-chloro-2-methylbenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-61-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 192756-62-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[3-(dimethylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-63-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-


(dimethylamino)benzoyl]amino]octahydro-  
 6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-  
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-65-3 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[ (6-methyl-1,3-benzodioxol-5-yl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-66-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-acetylbenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-68-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-hydroxy-2-methylbenzoyl)amino]-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-69-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-hydroxy-3-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-70-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-


(aminosulfonyl)benzoyl]amino]octahydro-  
 6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-  
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-71-1 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-(hydroxymethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-  
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-73-3 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-amino-3-chlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-  
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-74-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-amino-3,5-dichlorobenzoyl]amino]octahydro-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-75-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzoylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-76-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(2-methyl-1-oxopropyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-77-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxopropyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-78-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(phenylacetyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-79-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(3-methyl-1-oxobutyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-80-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxobutyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-81-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[[[(methylamino)carbonyl]amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-82-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-


[(methoxycarbonyl)amino]benzoyl

1]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]-

4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-83-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzyloxy)benzoyl]amino]octahydro-


6,10-

dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,

(3S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-84-6 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluoro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-86-8 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(phenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 192756-87-9 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-88-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-hydroxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo- (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-89-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-(phenylmethoxy)benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192762-50-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-  
 [(oxophenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220743-36-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[ (3-methyl-5-  
 isoxazolyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 1-  
 yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220743-37-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[ (1-methyl-1H-indol-3-  
 yl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220743-39-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(benzo[b]thien-3-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220743-43-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-benzofuranylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220743-44-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(2E)-1-oxo-3-(4-pyridinyl)-2-propenyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 220743-45-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1H-indol-3-ylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220743-47-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[3,4-bis(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220743-50-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(2E)-1-oxo-3-phenyl-2-propenyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IT 175211-62-8P 192753-72-3P 192753-74-5P  
192753-76-7P 192753-79-0P 192753-85-8P  
192753-87-0P 192753-91-6P 192753-92-7P  
192753-94-9P 192753-96-1P 192754-00-0P  
192754-01-1P 220744-52-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of bicyclic peptide derivs. as interleukin-1 $\beta$  converting enzyme inhibitors)

RN 175211-62-8 CAPLUS

CN Pentanoic acid, 5-[[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-72-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-74-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[phenylmethoxy]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-76-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-79-0 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-85-8 CAPLUS

CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-87-0 CAPLUS

CN 2-Benzoxazolebutanoic acid,  $\beta$ -[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro- $\gamma$ -oxo-, 1,1-dimethylethyl ester, ( $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-91-6 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[[(2-chlorophenyl)methyl]thio]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-92-7 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-94-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192753-96-1 CAPLUS

CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-00-0 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-01-1 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220744-52-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 48

THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1998:788773 CAPLUS Full-text  
 DN 130:66805  
 TI Preparation of peptide inhibitors of interleukin-1 $\beta$  converting enzyme  
 IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael  
 D.; Murcko, Mark A.; Livingston, David J.  
 PA Vertex Pharmaceuticals, Incorporated, USA  
 SO U.S., 106 pp., Cont.-in-part of U.S. 5,656,627.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5847135	A	19981208	US 1995-440898	19950525
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5656627	A	19970812	US 1995-405581	19950317
	US 5716929	A	19980210	US 1995-464964	19950605
	US 6103711	A	20000815	US 1995-465216	19950605
	TW 509698	B	20021111	TW 1995-84105903	19950609
	IN 181338	A	19980516	IN 1995-CA659	19950612
	CA 2192089	AA	19951228	CA 1995-2192089	19950616
	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9529446	A1	19960115	AU 1995-29446	19950616
	AU 709114	B2	19990819		
	EP 784628	A1	19970723	EP 1995-925257	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	CN 1159196	A	19970910	CN 1995-194381	19950616
	BR 9508051	A	19971021	BR 1995-8051	19950616
	HU 76622	A2	19971028	HU 1996-3475	19950616
	JP 10504285	T2	19980428	JP 1996-502478	19950616
	AP 797	A	20000107	AP 1997-960	19950616
	W: KE, MW, SD, SZ, UG				
	PL 185693	B1	20030731	PL 1995-318220	19950616
	EP 1394175	A1	20040303	EP 2003-22215	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE	NO 9605365	A	19970217	NO 1996-5365	19961213
	FI 9605036	A	19970214	FI 1996-5036	19961216
	BG 63634	B1	20020731	BG 1997-101130	19970114
	US 5973111	A	19991026	US 1997-828941	19970328
	IN 183119	A	19990911	IN 1997-CA778	19970430
	US 6420522	B1	20020716	US 1999-430822	19991029
	US 2002099042	A1	20020725	US 2001-886773	20010621
PRAI	US 1994-261452	A2	19940617		
	US 1995-405581	A2	19950317		
	US 1995-440898	A3	19950525		
	US 1995-465216	A3	19950605		
	IN 1995-CA659	A1	19950612		

EP 1995-925257 A3 19950616  
 WO 1995-US7617 W 19950616  
 US 1999-430822 A3 19991029

OS MARPAT 130:66805

AB Interleukin-1 $\beta$  converting enzyme inhibitors R1NHX1[(CH<sub>2</sub>)<sub>m</sub>T](CH<sub>2</sub>)<sub>g</sub>R3 (X1 = CH, N; g = 0, 1; m = 0-2; T = a cyclic group, OH, CF<sub>3</sub>, COCO<sub>2</sub>H, CO<sub>2</sub>H; R1 = R4ZNR5CR6R7CO or substituted derivs., where R4 represents certain ring systems; R5 = H, a cyclic group, alkyl, arylcarbonyl, arylsulfonyl, etc.; CR6R7 form a saturated carbocyclic or heterocyclic ring; R3 = CN, 1-alkenyl, alkoxyiminomethyl) were prepared. Thus, N-(N-acetyltyrosinylvalinylpipecolyl)-3-amino-4-oxobutanoic acid was prepared and showed IC<sub>50</sub> = 6-11  $\mu$ M for inhibition of interleukin-1 $\beta$  converting enzyme.


IT 175209-10-6P 175209-11-7P 175209-35-5P  
 175209-36-6P 175209-41-3P 175209-44-6P  
 175209-48-0P 175209-61-7P 175209-93-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of peptide inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-35-5 CAPLUS

CN 2-Benzoxazolebutanoic acid, 7-methoxy- $\beta$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\gamma$ -oxo-, ( $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-41-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methanysulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-44-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methanysulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-48-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-61-7 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-93-5 CAPLUS

CN Pentanoic acid, 5-[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 175211-62-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent) (preparation of peptide inhibitors of  
 interleukin-1 $\beta$  converting enzyme)

RN 175211-62-8 CAPLUS

CN Pentanoic acid, 5-[[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-  
 6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-  
 a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester,  
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 50

THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:541852 CAPLUS Full-text

DN 127:234612

TI Preparation of heterocyclyl aspartaldehyde peptide derivatives as interleukin-1 $\beta$  converting enzyme inhibitors

IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael D.; Murcko, Mark A.; Livingston, David J.

PA Vertex Pharmaceuticals, Inc., USA

SO U.S., 67 pp., Cont.-in-part of U.S. Ser. No. 261,452.

CODEN: USXXAM

DT Patent





LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5656627	A	19970812	US 1995-405581	19950317
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5847135	A	19981208	US 1995-440898	19950525
	US 5716929	A	19980210	US 1995-464964	19950605
	US 6025147	A	20000215	US 1995-460973	19950605
	TW 509698	B	20021111	TW 1995-84105903	19950609
	IN 181338	A	19980516	IN 1995-CA659	19950612
	ZA 9504988	A	19961217	ZA 1995-4988	19950615
	CA 2192089	AA	19951228	CA 1995-2192089	19950616
	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9529446	A1	19960115	AU 1995-29446	19950616
	AU 709114	B2	19990819		
	EP 784628	A1	19970723	EP 1995-925257	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	CN 1159196	A	19970910	CN 1995-194381	19950616
	BR 9508051	A	19971021	BR 1995-8051	19950616
	HU 76622	A2	19971028	HU 1996-3475	19950616
	JP 10504285	T2	19980428	JP 1996-502478	19950616
	AP 797	A	20000107	AP 1997-960	19950616
	W: KE, MW, SD, SZ, UG				
	PL 185693	B1	20030731	PL 1995-318220	19950616
	EP 1394175	A1	20040303	EP 2003-22215	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE	NO 9605365	A	19970217	NO 1996-5365	19961213
	FI 9605036	A	19970214	FI 1996-5036	19961216
	BG 63634	B1	20020731	BG 1997-101130	19970114
	US 5973111	A	19991026	US 1997-828941	19970328
	IN 183119	A	19990911	IN 1997-CA778	19970430
	US 6420522	B1	20020716	US 1999-430822	19991029
	US 2002099042	A1	20020725	US 2001-886773	20010621
PRAI	US 1994-261452	A2	19940617		
	US 1995-405581	A2	19950317		
	US 1995-440898	A3	19950525		

US 1995-465216	A3	19950605
IN 1995-CA659	A1	19950612
EP 1995-925257	A3	19950616
WO 1995-US7617	W	19950616
US 1999-430822	A3	19991029

OS MARPAT 127:234612  
GI



AB The present invention relates to novel classes of compds. I [X1 = CH, N; q = 0, 1; J = independently H, OH, F; m = 0-2; T = Ar3, OH, CF3, COCO2H, CO2H, COCH2OH, CONHOH, SO2NHR, SO3H, P(O)(OH)NH2, CONHCN, OSO3H, CONHSO2R16, PO3H2, P(O)(OH)OR16, P(O)(OH)R16, OPO3H2, OP(O)(OH)OR16, OP(O)(OH)R16, NHPO3H2, NHP(O)(OH)OR16, NHP(O)(OH)R16, COCH:C(OH)CO2H, 5- or 6-membered heterocyclic ring; R16 = C1-6 alkyl; R1 = optionally substituted fragment Q; X2 = O, CH2, NH, S, S(O), SO2; X5 = CH, N; n = 0-1, d = 0-2, such that n + d + d = 2; R3 = CN, CH:CHR9, CH:NOR9, (CH2)1-3T1R9, CJ2R9, COR13, COCONR5R10; each R4 = H, Ar1, R9, T1R9, (CH2)1-3T1R9; each T1 = CH:CH, O, S, S(O), SO2, NR10, NR10CO, CO, O2C, CO2, CONR10, O2CNR10, NR10CONR10, SO2NR10, NR10SO2, NR10SO2NR10; R5 = H, Ar1, COAr1, SO2Ar1, R9, CONR9, CO2R9, SO2R9, CONAr1R10, SO2NAr1R10, CONR9R10, SO2NR9R10; R5 = Ar1, SO2Ar1, COR9, CONAr1R10, SO2NAr1R10, CONR9R10, SO2NR9R10; R9 = optionally substituted, straight or branched C1-6 alkyl; R10 = H, C1-6 straight or branched alkyl; R13 = H, Ar1, Ar2, R9, T1R9, (CH2)1-3T1R9; Ar1 = aryl, cycloalkyl, or heterocyclyl group containing 1-3 rings and 3-15 ring atoms; Ar2 = optionally benzo-fused 5-membered heterocyclyl; Ar3 = optionally substituted Ph or 5-membered heterocyclic ring] which are inhibitors of interleukin-1 $\beta$  converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochem. features. This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compds. and compns. of this invention. Thus,

cyclocondensation of Et 2-aminopyrrolidine-5- carboxylate with 4-ethoxymethylene-2-phenyl-2-oxazolidin-2-one gave 32% pyrrolopyrimidine II. Saponification of II, followed by coupling with tert-Bu (3S)-amino-4-oxobutanoate semicarbazone, diastereomer separation, and deprotection, gave ICE inhibitors III. III and related compds. inhibited ICE with  $K_i$  = 0.011 to 35  $\mu$ M in a UV-visible assay and  $IC_{50}$  = 0.50 to >35  $\mu$ M in a cell assay.

IT 175209-10-6P 175209-11-7P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclyl aspartaldehyde peptide derivs. as interleukin-1 $\beta$  converting enzyme inhibitors)

RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-

4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-

4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



App's

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1997:502830 CAPLUS Full-text  
DN 127:122000

TI Inhibitors of interleukin-1 $\beta$  converting enzyme  
IN Batchelor, Mark J.; Bebbington, David; Bemis, Guy W.; Fridman, Wolf  
Herman; Gillespie, Roger J.; Golec, Julian M. C.; Gu, Yong; Lauffer,  
David J.; Livingston, David J.; Matharu, Saroop S.; Mullican, Michael  
D.; Murcko, Mark A.; Murdoch, Robert; Nyce, Philip L.; Robidoux, Andrea  
L. C.; et al.

PA USA  
SO PCT Int. Appl., 946 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6008217	A	19991228	US 1995-575641	19951220
	US 5874424	A	19990223	US 1996-598332	19960208
	US 5985863	A	19991116	US 1996-712878	19960912
	US 6204261	B1	20010320	US 1996-761483	19961206
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9612258	A	19990713	BR 1996-12258	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	AU 756253	B2	20030109	AU 2001-76122	20010928
PRAI	US 1995-575641	A	19951220		
	US 1996-598332	A	19960208		
	US 1996-712878	A	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	WO 1996-US20843	W	19961220		

OS MARPAT 127:122000

AB Compds. R(CH<sub>2</sub>)<sub>n</sub>CH(NHR<sub>1</sub>)(CR<sub>22</sub>)mR<sub>3</sub> [R = NC, R<sub>4</sub>CH:CH, R<sub>4</sub>ON:CH, R<sub>4</sub>CR<sub>22</sub>, etc. where R<sub>2</sub> is independently selected from H, OH, F and R<sub>4</sub> is (un)substituted alkyl; R<sub>1</sub> = R<sub>5</sub>NHCHR<sub>6</sub>CONR<sub>7</sub>CHR<sub>8</sub>CO, where CHR<sub>6</sub>CONR<sub>7</sub> is a 2-oxoazepine ring substituted by benzo, pyrido, thieno, or related rings at the 6,7-position and optionally may have O, NH, S, SO, or SO<sub>2</sub> at the 5-position, R<sub>5</sub> and R<sub>8</sub> are H, cyclic group, etc.; R<sub>3</sub> = OH, COCOCO<sub>2</sub>H, CO<sub>2</sub>H, or any bioisosteric replacement for CO<sub>2</sub>H; m = 0, 1, 2; n = 0, 1]

were prepared as inhibitors of interleukin-1 $\beta$  converting enzyme. Thus, [1S,9S(2RS,3S)]-9- benzoylamino-6,10-dioxo-1,2,3,4,7,8,9,10-octahydro-N-(2-benzyloxy-5- oxotetrahydrofuran-3-yl)-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamide was prepared and shown to have IC50 values of 900 and 600 nM, resp., in the peripheral blood mononuclear cell (PBMC) and whole human blood assays.

IT 192754-50-0P 192755-43-4P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological


study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 192754-50-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192755-43-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174799-05-4P 174799-23-6P 175209-10-6P  
175209-11-7P 175209-35-5P 175209-36-6P  
175209-41-3P 175209-44-6P 175209-48-0P  
175209-61-7P 192753-76-7P 192754-51-1P

192754-52-2P 192754-53-3P 192754-54-4P  
 192754-56-6P 192754-57-7P 192754-59-9P  
 192754-61-3P 192754-76-0P 192754-98-6P  
 192755-26-3P 192755-28-5P 192755-30-9P  
 192755-31-0P 192755-32-1P 192755-33-2P  
 192755-40-1P 192755-94-5P 192755-95-6P  
 192755-99-0P 192756-00-6P 192756-01-7P  
 192756-02-8P 192756-03-9P 192756-04-0P  
 192756-07-3P 192756-10-8P 192756-12-0P  
 192756-28-8P 192756-32-4P 192756-36-8P  
 192756-44-8P 192756-46-0P 192756-50-6P  
 192756-63-1P 192756-67-5P 192756-73-3P  
 192756-78-8P 192756-79-9P 192756-90-4P  
 192756-91-5P 192759-92-5P 192759-98-1P  
 192762-50-8P


RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic  
 use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 174799-05-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-  
 dioxo-9-[[ (phenylmethoxy) carbonyl] amino]-6H-pyridazino[1,2-  
 a][1,2]diazepin-  
 1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 174799-23-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-  
 pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-35-5 CAPLUS

CN 2-Benzoxazolebutanoic acid, 7-methoxy-beta-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-gamma-oxo-, (betaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-41-3 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175209-44-6 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-48-0 CAPLUS  
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-61-7 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)- $\beta$ -[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\gamma$ -oxo-, ( $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192753-76-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-51-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-52-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-53-3 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methanesulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-54-4 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192754-56-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-57-7 CAPLUS

CN 2-Benzoxazolebutanoic acid,  $\beta$ -[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro- $\gamma$ -oxo-, ( $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-59-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[[2-chlorophenyl)methyl]thio]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-61-3 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-76-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-98-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,8S,9S)-9-(benzoylamino)octahydro-8-methyl-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-26-3 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-28-5 CAPLUS

CN Sulfonium, [(3S)-3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl][(2-chlorophenyl)methyl]methyl-, tetrafluoroborate(1-) (9CI)


(CA INDEX NAME)

CM 1

CRN 192755-27-4

CMF C30 H34 Cl N4 O7 S

Absolute stereochemistry.




CM 2

CRN 14874-70-5

CMF B F4


CCI CCS



RN 192755-30-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-31-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-32-1 CAPLUS

CN Benzoic acid, 2,6-dimethyl-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192755-33-2 CAPLUS


CN 1-Naphthalenecarboxylic acid, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192755-40-1 CAPLUS  
 CN Butanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, ethyl ester,  
 [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192755-94-5 CAPLUS  
 CN Butanoic acid, 3-[[[9-[[4-(acetylamino)-3-chlorobenzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-  
 [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192755-95-6 CAPLUS  
 CN Butanoic acid, 3-[[[9-[(3,5-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,  
 [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192755-99-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,

(3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-00-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,

(3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-01-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-chlorobenzoyl)amino]octahydro-6,10-


6H-pyridazino[1,2-a][1,2]diazepin-1-yl] carbonyl] amino]-4-oxo-, (3S)-  
(9CI)

Absolute stereochemistry.




192/50-52-9 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(2-naphthalenylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

Absolute stereochemistry.



CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-naphthalenylcarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-


Absolute stereochemistry.



RN 192756-04-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[[1,1'-biphenyl]-4-yl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-07-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1-isoquinolinyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-10-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-chlorobenzoyl)amino]octahydro-6,10-


dioxo-  
 6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
 (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-12-0 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(acetylamino)benzoyl]amino]octahydro-  
 6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-  
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-28-8 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[1H-benzimidazol-5-  
 ylcarbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-  
 1-  
 yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-32-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(6-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-36-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(thieno[2,3-b]thien-2-ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-44-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[3-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-46-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,

(3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-50-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(4-hydroxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,

(3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-63-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(dimethylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-67-5 CAPLUS

CN Butanoic acid, 3-[[[octahydro-9-[(1H-indol-2-ylcarbonyl)amino]-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-73-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-amino-3-chlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-78-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(phenylacetyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-79-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(3-methyl-1-oxobutyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-90-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(4-chlorophenyl)amino]oxoacetyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-91-5 CAPLUS

CN Butanoic acid, 3-[[[9-[[2,6-dimethoxyphenyl]oxoacetyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-92-5 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-98-1 CAPLUS

CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192762-50-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(oxophenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174799-04-3 192759-91-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 174799-04-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-  
[[ (phenylmethoxy) carbonyl] amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl] carbonyl] amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-91-4 CAPLUS

CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-  
pyridazino[1,2-a][1,2]diazepin-1-yl] carbonyl] amino]-5-bromo-4-oxo-,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 175211-62-8P 192753-72-3P 192753-74-5P  
192753-79-0P 192753-85-8P 192753-91-6P  
192753-92-7P 192753-94-9P 192753-96-1P  
192754-00-0P 192754-01-1P 192754-08-8P  
192754-09-9P 192754-46-4P 192757-33-8P  
192757-35-0P 192757-38-3P 192757-41-8P  
192757-44-1P 192757-46-3P 192757-47-4P  
192757-48-5P 192757-49-6P 192759-71-0P  
192759-72-1P 192759-74-3P 192759-75-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)


(inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 175211-62-8 CAPLUS

CN Pentanoic acid, 5-[[ (2-chlorophenyl) methyl] thio]-3-[[[(1S,9S)-octahydro-

6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-72-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(1S,9S)-9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-74-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-79-0 CAPLUS

CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-85-8 CAPLUS

CN 2-Benzoxazolebutanoic acid, 5,7-dichloro-β-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, 1,1-dimethylethyl ester, (βS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-91-6 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[2-chlorophenyl)methyl]thio]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-92-7 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[(2-chlorophenyl)methoxy]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-94-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192753-96-1 CAPLUS

CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-00-0 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-01-1 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 192754-08-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[[(2,6-dichlorophenyl)methoxy]imino]-, 1,1-dimethylethyl ester, (3S)- (9CI)

(CA  
INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 192754-09-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 192754-46-4 CAPLUS

CN Butanoic acid, 3-[[[9-[(3,5-dichloro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN 1-Naphthalenecarboxylic acid, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[ (methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]-(9CI) (CA INDEX NAME)


The chemical structure shows a complex molecule. On the left, a methylsulfonamide group (Me-SO<sub>2</sub>-NH-) is connected via a dashed line to a bicyclic system. This system consists of a seven-membered ring fused to a six-membered ring, both containing sulfur (S) and nitrogen (N) atoms, with carbonyl (C=O) groups. The seven-membered ring is also connected via a dashed line to a chain containing a sulfur atom (S), a carbonyl group (C=O), and a tert-butyl ester group (OBu-t). This chain is further connected via a dashed line to a naphthalene ring system, which is linked to another carbonyl group (C=O) and an ester group (O-C=O).

CN 4-Isoxazolecarboxylic acid, 5-methyl-3-phenyl-, 5-(1,1-dimethylethoxy)-  
3-  
[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Chemical structure of compound 10, showing a complex molecule with a benzothiazepine core, a sulfonamide group, and a 1,3-dioxane derivative.

CN Benzoic acid, 2-phenoxy-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-41-8 CAPLUS

CN Benzoic acid, 3-phenoxy-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-44-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-methyl-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-46-3 CAPLUS

CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-diazo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-47-4 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-48-5 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-49-6 CAPLUS

CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-diazo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-71-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-72-1 CAPLUS

CN Benzoic acid, 2,6-dimethyl-, 5-(1,1-dimethylethoxy)-3-[[[octahydro-9-  
[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2,5-dioxopentyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-74-3 CAPLUS

CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-  
pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-  
1H-  
tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-  
[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-75-4 CAPLUS

CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-  
pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-  
pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 175209-93-5P 192753-87-0P 192753-95-0P  
 192753-97-2P 192754-02-2P 192754-03-3P  
 192754-10-2P 192754-11-3P 192755-29-6P  
 192755-34-3P 192756-96-0P 192757-06-5P  
 192757-24-7P 192757-36-1P 192757-39-4P  
 192757-42-9P 192757-45-2P 192757-50-9P  
 192757-51-0P 192759-69-6P 192759-70-9P  
 192759-73-2P 192759-80-1P 192759-81-2P  
 192759-82-3P 192759-83-4P 192759-84-5P  
 192759-85-6P 192759-86-7P 192759-87-8P  
 192759-88-9P 192759-89-0P 192759-90-3P  
 192759-93-6P 192759-96-9P 192759-97-0P  
 192760-00-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 175209-93-5 CAPLUS

CN Pentanoic acid, 5-[[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 192753-87-0 CAPLUS

CN 2-Benzoxazolebutanoic acid,  $\beta$ -[[[(1S,9S)-9-(benzoylamino)octahydro-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5,7-dichloro- $\gamma$ -oxo-, 1,1-dimethylethyl ester, ( $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192753-95-0 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-fluoro-4-oxo- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 192753-97-2 CAPLUS

CN Propanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-3-cyano-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-02-2 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-03-3 CAPLUS

CN Pentanoic acid, 4-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-oxo-, (4R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192754-10-2 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[[2,6-dichlorophenyl)methoxy]imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 192754-11-3 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(2-phenylethoxy)imino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 192755-29-6 CAPLUS  
CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192755-34-3 CAPLUS  
 CN 2-Thiophenecarboxylic acid, 3-chloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-96-0 CAPLUS  
 CN Butanoic acid, 4-(methoxyimino)-3-[[[octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.



RN 192757-06-5 CAPLUS  
 CN Butanoic acid, 3-[[[octahydro-9-[(4-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-[(phenylmethoxy)imino]-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.




RN 192757-24-7 CAPLUS

CN Butanoic acid, 3-[[[octahydro-9-[(4-hydroxy-3,5-dimethylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-36-1 CAPLUS

CN 4-Isoxazolecarboxylic acid, 5-methyl-3-phenyl-, 4-carboxy-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 192757-39-4 CAPLUS

CN Benzoic acid, 2-phenoxy-, 4-carboxy-3-[[[octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 192757-42-9 CAPLUS

CN Benzoic acid, 3-phenoxy-, 4-carboxy-3-[[[octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 192757-45-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-methyl-, 4-carboxy-3-[[[octahydro-9-  
[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 192757-50-9 CAPLUS

CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-bromo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192757-51-0 CAPLUS


CN Pentanoic acid, 5-bromo-3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192759-69-6 CAPLUS  
 CN Pentanoic acid, 5-bromo-3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192759-70-9 CAPLUS  
 CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-bromo-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-73-2 CAPLUS  
 CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-thiazolylythio)-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-80-1 CAPLUS

CN 1(6H)-Pyrimidinepentanoic acid,  $\beta$ -[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\gamma$ ,6-dioxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-81-2 CAPLUS

CN 1(6H)-Pyrimidinepentanoic acid,  $\beta$ -[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]- $\gamma$ ,6-dioxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192759-82-3 CAPLUS

CN Pentanoic acid, 5-[(3-chloro-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)oxy]-3-

3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192759-83-4 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-


tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192759-84-5 CAPLUS  
 CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192759-85-6 CAPLUS  
 CN Pentanoic acid, 3-[[[octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]-(9CI) (CA INDEX NAME)


COC(=O)N[C@@H]1C(=O)N2C(=O)N(C2)C[C@H]1S[C@@H](C(=O)N[C@@H]3C(=O)N(C(=O)OCC4=CN=CC=C4)C3=O)S3

CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(2-pyrimidinylthio)-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

COC(=O)N[C@@H]1C(=O)N2C(=O)N[C@@H](C(=O)N[C@@H](CS(=O)CCSC3=NC=CC=N3)C(=O)O)C(=O)N2S1

CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-89-0 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-90-3 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-93-6 CAPLUS

CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 192759-96-9 CAPLUS

CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192759-97-0 CAPLUS

CN Pentanoic acid, 3-[[[9-(acetylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192760-00-2 CAPLUS

CN Butanoic acid, 3-[[[9-(benzoylamino)octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\beta$ ]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174799-28-1P 192756-05-1P 192756-06-2P  
 192756-08-4P 192756-09-5P 192756-11-9P  
 192756-13-1P 192756-14-2P 192756-15-3P  
 192756-16-4P 192756-17-5P 192756-18-6P  
 192756-19-7P 192756-20-0P 192756-21-1P  
 192756-22-2P 192756-23-3P 192756-24-4P  
 192756-25-5P 192756-26-6P 192756-27-7P  
 192756-29-9P 192756-30-2P 192756-31-3P  
 192756-33-5P 192756-34-6P 192756-35-7P  
 192756-37-9P 192756-38-0P 192756-39-1P  
 192756-40-4P 192756-41-5P 192756-42-6P  
 192756-43-7P 192756-45-9P 192756-47-1P  
 192756-48-2P 192756-49-3P 192756-51-7P  
 192756-52-8P 192756-53-9P 192756-54-0P  
 192756-55-1P 192756-56-2P 192756-57-3P  
 192756-58-4P 192756-59-5P 192756-60-8P  
 192756-61-9P 192756-62-0P 192756-64-2P  
 192756-65-3P 192756-66-4P 192756-68-6P  
 192756-69-7P 192756-70-0P 192756-71-1P  
 192756-72-2P 192756-74-4P 192756-75-5P  
 192756-76-6P 192756-77-7P 192756-80-2P  
 192756-81-3P 192756-82-4P 192756-83-5P  
 192756-84-6P 192756-85-7P 192756-86-8P  
 192756-87-9P 192756-88-0P 192756-89-1P  
 192756-92-6P 192766-55-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)

(inhibitors of interleukin-1 $\beta$  converting enzyme)


RN 174799-28-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 192756-05-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-thienylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-06-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(2-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




```

RN      192756-08-4   CAPLUS
CN      Butanoic acid, 3-[[[(1S,9S)-9-[(cyclopropylcarbonyl)amino]octahydro-
6,10-
        dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,
(3S)-
        (9CI)  (CA INDEX NAME)


```

Absolute stereochemistry.



RN 192756-09-5 CAPLUS  
CN Butanoic acid, 3-[[[(1S,9S)-9-[(1,3-benzodioxol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN	192756-11-9	CAPLUS
CN	Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3,4,5-	

trimethoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-13-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methoxycarbonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-14-2 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methylamino)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-15-3 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(ethylsulfonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-16-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[[1-ethyl-3-methyl-1H-pyrazol-5-yl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-17-5 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[2,4-dimethyl-5-thiazolyl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-18-6 CAPLUS

CN Butanoic acid, 3-[[[octahydro-9-[[5-methyl-3-isoxazolyl)carbonyl]amino]-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-19-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[6-hydroxy-2-naphthalenyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-

1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-20-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(cyclohexylcarbonyl)amino]octahydro-6,10-


dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,  
 (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-21-1 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-  
 [(phenylsulfonyl)amino]-  
 6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
 (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-22-2 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[[(dimethylamino)sulfonyl]amino]octahydro-  
 6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-  
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-23-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-aminooctahydro-6,10-dioxo-6H-pyridazino[1,2-

a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-24-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[2-(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-25-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-aminobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 192756-26-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(1H-benzotriazol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-27-7 CAPLUS

CN Butanoic acid, 3-[[[octahydro-9-[[[(1-methyl-1H-indol-2-yl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-29-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-30-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-31-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-methoxy-2-quinolinyl]carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-33-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(8-quinolinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-34-6 CAPLUS


CN Butanoic acid, 3-[[[(1S,9S)-9-[[[(3-amino-2-naphthalenyl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-35-7 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[[4-(dimethylamino)-1-naphthalenyl]carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-37-9 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(4-phenoxybenzoyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-38-0 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(2,6-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-39-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(1H-imidazol-2-ylcarbonyl)amino]-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-40-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1,2,3-thiadiazol-5-ylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-

oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-41-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-


[(methylsulfonyl)amino]benzoyl  
 ]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-  
 yl]carbonyl]amino]-  
 4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-42-6 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(  
 (acetylmethylamino)benzoyl]amino]octahyd  
 ro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-  
 oxo-  
 , (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-43-7 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[[(1-hydroxy-2-  
 naphthalenyl)carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-  
 a][1,2]diazepin-  
 1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-45-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-methoxybenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-47-1 CAPLUS

CN Butanoic acid, 3-[[[9-[(benzo[b]thien-2-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-48-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(3-pyridinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-49-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chlorobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 192756-51-7 CAPLUS

CN Benzoic acid, 4-hydroxy-, 4-[[[(4S,7S)-4-[[[(1S)-2-carboxy-1-formylethyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-52-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-difluorobenzoyl)amino]octahydro-6,10-

dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-53-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-fluorobenzoyl)amino]octahydro-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-54-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-(methylsulfonyl)benzoyl]amino]-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-55-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluorobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-56-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-fluorobenzoyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
(9CI)


(CA INDEX NAME)

Absolute stereochemistry.




RN 192756-57-3 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(3,4-dichlorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-58-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-2-methylbenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-59-5 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(5-chloro-2-methylbenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-60-8 CAPLUS

CN Butanoic acid, 3-[[[9-[(2-benzofuranylcarbonyl)amino]octahydro-6,10-dioxo-

6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,

[1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-61-9 CAPLUS

CN Butanoic acid, 3-[[[1S,9S)-octahydro-9-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-62-0 CAPLUS

CN Butanoic acid, 3-[[[1S,9S)-9-[[[3-(dimethylamino)benzoyl]amino]octahydro-

6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-64-2 CAPLUS

CN Butanoic acid, 3-[[[octahydro-6,10-dioxo-9-[[1-oxo-3-(4-pyridinyl)-2-propenyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-

oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 192756-65-3 CAPLUS


CN Butanoic acid, 3-[[[[(1S,9S)-octahydro-9-[[6-methyl-1,3-benzodioxol-5-yl]carbonyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-66-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[(4-acetylbenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-68-6 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(3-hydroxy-2-methylbenzoyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-69-7 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-hydroxy-3-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-70-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(aminosulfonyl)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-

(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-71-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-(hydroxymethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-


(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-72-2 CAPLUS  
 CN Butanoic acid, 3-[[[9-[[3,5-bis(acetylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-74-4 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-amino-3,5-dichlorobenzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 192756-75-5 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzoylamino)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-76-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(2-methyl-1-oxopropyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-77-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxopropyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-80-2 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-[(1-oxobutyl)amino]benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-81-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(methylamino)carbonyl]amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-82-4 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[[4-[(methoxycarbonyl)amino]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-83-5 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[[4-(benzoyloxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-84-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-fluoro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 192756-85-7 CAPLUS

CN Butanoic acid, 3-[[[octahydro-6,10-dioxo-9-[(1-oxo-3-phenyl-2-propenyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 192756-86-8 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(phenylacetyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-87-9 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-methoxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-88-0 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-[(3-chloro-4-hydroxybenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-89-1 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[4-(phenylmethoxy)benzoyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192756-92-6 CAPLUS

CN Butanoic acid, 3-[[[9-[[4-(acetylamino)-3,5-dichlorobenzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.




RN 192766-55-5 CAPLUS

CN Butanoic acid, 3-[[[9-[[4-(acetyloxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:397284 CAPLUS Full-text  
 DN 127:44456  
 TI Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of Interleukin-1 $\beta$ -Converting Enzyme Inhibitor  
 AU Dolle, Roland E.; Prasad, C. V. C.; Prouty, Catherine P.; Salvino, Joseph M.; Awad, Mohamed M. A.; Schmidt, Stanley J.; Hoyer, Denton; Ross, Tina Morgan; Graybill, Todd L.; Speier, Gary J.; Uhl, Joanne; Miller, Robert; Helaszek, Carla T.; Ator, Mark A.  
 CS Sanofi Winthrop Inc., Collegeville, PA, 19426, USA  
 SO Journal of Medicinal Chemistry (1997), 40(13), 1941-1946  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI



AB The pyridazinodiazepine-based peptidomimetics are potent time-dependent inactivators of interleukin-1 $\beta$  converting enzyme ( $k_{obs}/[I] = 162,000$  to  $1,220,000 \text{ M}^{-1} \text{ s}^{-1}$ ). The corresponding aspartic acid aldehyde analogs are potent reversible inhibitors of the enzyme with inhibition consts. ranging from 1-50 nM. All of these inhibitors retain the P1 aspartic acid residue and critical hydrogen-bonding functionality, P1 and P3 NH, which are structural elements previously shown to be required for potent enzyme inhibition by peptide-based inhibitors. In addition, inhibitor I exhibits 10-15% oral bioavailability in the dog.


IT 174799-03-2P 174799-04-3P 174799-05-4P  
 174799-06-5P 174799-07-6P 174799-10-1P  
 174799-15-6P 174799-16-7P 174799-17-8P  
 174799-22-5P 174799-23-6P 174799-24-7P  
 174799-28-1P

RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
 study); PREP (Preparation)  
 (pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class  
 of  
 interleukin-1 $\beta$ -converting enzyme inhibitor)

RN 174799-03-2 CAPLUS

CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,  
 [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-04-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-05-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 174799-06-5 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-6,10-dioxo-9-  
[[phenylmethoxy)carbonyl]amin  
o]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[[1-  
phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, [1S-  
[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-07-6 CAPLUS

CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-  
yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[phenylmethoxy)carbonyl]amino]-6H-  
pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-10-1 CAPLUS

CN Pentanoic acid, 3-[[[9-[[4-[(carboxymethyl)thio]benzoyl]amino]octahydro-  
6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-  
(4-  
chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-15-6 CAPLUS


CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

Cl



PAGE 1-B

RN 174799-16-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(4-methyl-


1-

piperazinyl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

Cl



PAGE 1-B




RN 174799-17-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(2-methyl-1H-

imidazol-1-yl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-22-5 CAPLUS

CN Benzenebutanoic acid, 4-[[[4-[[[1-(carboxymethyl)-3-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, [4S-[4 $\alpha$ (R\*),7 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—CF<sub>3</sub>

RN 174799-23-6 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-24-7 CAPLUS

CN Butanoic acid, 3-[[[9-[[4-(carboxymethoxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-28-1 CAPLUS


CN Butanoic acid, 3-[[[1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:214750 CAPLUS Full-text  
 DN 124:290273  
 TI Preparation of peptide analogs as inhibitors of interleukin-1 beta  
 converting enzyme (ICE)  
 IN Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.; Mullican, Michael  
 D.; Murcko, Mark A.; Livingston, David J.  
 PA Vertex Pharmaceuticals Incorp., USA  
 SO PCT Int. Appl., 374 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9535308	A1	19951228	WO 1995-US7617	19950616
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5756466	A	19980526	US 1994-261452	19940617
	US 5656627	A	19970812	US 1995-405581	19950317
	US 5847135	A	19981208	US 1995-440898	19950525
	AU 9529446	A1	19960115	AU 1995-29446	19950616
	AU 709114	B2	19990819		
	EP 784628	A1	19970723	EP 1995-925257	19950616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	BR 9508051	A	19971021	BR 1995-8051	19950616
	JP 10504285	T2	19980428	JP 1996-502478	19950616
	AP 797	A	20000107	AP 1997-960	19950616
	W: KE, MW, SD, SZ, UG				
	PL 185693	B1	20030731	PL 1995-318220	19950616
	NO 9605365	A	19970217	NO 1996-5365	19961213
	FI 9605036	A	19970214	FI 1996-5036	19961216
	BG 63634	B1	20020731	BG 1997-101130	19970114
	US 6420522	B1	20020716	US 1999-430822	19991029
PRAI	US 1994-261452	A	19940617		
	US 1995-405581	A	19950317		
	US 1995-440898	A	19950525		
	US 1995-465216	A3	19950605		
	WO 1995-US7617	W	19950616		
OS	MARPAT 124:290273				
GI					



AB Novel classes of compds. are prepared, which are characterized by specific structural and physicochem. features comprising (a) a first and a second hydrogen bonding moiety, each of said moieties being capable of forming a hydrogen bond with a different backbone atom of ICE selected from the carbonyl O and the amide NH group of Arg-341 Ser-339, (b) a first and a second moderately hydrophobic moiety, said moieties each being capable of associating with a sep. binding pocket of ICE when the inhibitor is bound thereto, said binding pocket being selected from the P2, P3, P4, and P' binding pockets, and (c) an electroneg. moiety comprising  $\geq 1$  electroneg. atoms, said atoms being attached to the same atom or to adjacent atoms in the moiety and said moiety being capable of forming  $\geq 1$  hydrogen bonds or salts bridges with residues in the P1 binding pocket of ICE. These compds. and pharmaceutical compns. of this invention are particularly well suited for inhibiting ICE activity and consequently may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. Thus, etherification of Me N-tert-butoxycarbonyl-cis-4-hydroxyproline with phenol using Ph3P and di-Et azodicarboxylate in THF to Me N-tert-butoxycarbonyl-cis-4-phenoxyproline followed by deprotection with HCl in EtOAc to Me 4-phenoxyproline hydrochloride and condensation with Ac-Tyr-Val-OH using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HOBT, and diisopropylethylamine in DMF gave Me N-acetyl-L-tyrosinyl-L-valyl-(4-phenoxy)proline. Saponification of the latter peptide ester with LiOH in aqueous THF to N-acetyl-L-tyrosinyl-L-valyl-(phenoxy)proline followed by condensation with N-allyloxycarbonyl-4-amino-5-benzoyloxy-2-oxotetrahydrofuran gave N-[N-acetyl-L-tyrosinyl-L-valyl-(4-phenoxy)prolinyl]-4-amino-5-benzoyloxy-2-oxotetrahydrofuran (1:1 diastereomer mixture), which underwent hydrogenolysis over Pd(OH)<sub>2</sub> in MeOH under H atmospheric to give the title compound (I). In a IL-1 $\beta$  assay with a mixed population of human peripheral blood mononuclear cells or enriched adherent mononuclear cells, I in vitro showed IC<sub>50</sub> of 2.6 and 0.25  $\mu$ M for inhibiting the processing of pre-IL-1 $\beta$  by ICE.


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptide analogs as inhibitors of interleukin-1 beta converting enzyme for treating inflammatory, autoimmune and neurodegenerative diseases)

RN 175209-10-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-11-7 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-10-oxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-35-5 CAPLUS

CN 2-Benzoxazolebutanoic acid, 7-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-36-6 CAPLUS

CN 2-Benzoxazolebutanoic acid, 4-methoxy-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 175209-41-3 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175209-44-6 CAPLUS  
 CN Butanoic acid, 3-[[[(1S,9S)-octahydro-9-[(methylsulfonyl)amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175209-48-0 CAPLUS  
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175209-61-7 CAPLUS  
 CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)-β-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-γ-oxo-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175209-93-5 CAPLUS  
 CN Pentanoic acid, 5-[[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 175211-62-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent) (preparation of peptide analogs as inhibitors of interleukin-1 beta converting enzyme for treating inflammatory, autoimmune and neurodegenerative diseases)

RN 175211-62-8 CAPLUS


CN Pentanoic acid, 5-[[[(2-chlorophenyl)methyl]thio]-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[(1-oxo-3-phenylpropyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:190878 CAPLUS Full-text  
 DN 124:261732  
 TI Preparation of N-(oxodiazabicycloalkylcarbonyl)aspartates as  
 interleukin-1 $\beta$  converting enzyme inhibitors  
 IN Dolle, Roland E.; Chaturvedula, Prasad V.; Morgan, Ross Tina; Schmidt,  
 Stanley J.  
 PA Sanofi Winthrop, Inc., USA  
 SO PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9533751	A1	19951214	WO 1995-US7314	19950608
	W: AU, CA, HU, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5552400	A	19960903	US 1994-255276	19940608
	US 5639745	A	19970617	US 1995-451108	19950525
	AU 9527699	A1	19960104	AU 1995-27699	19950608
	AU 705882	B2	19990603		
	EP 764167	A1	19970326	EP 1995-923013	19950608
	EP 764167	B1	20031022		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
SE	HU 76334	A2	19970828	HU 1996-3376	19950608
	JP 10501244	T2	19980203	JP 1995-501315	19950608
	AT 252585	E	20031115	AT 1995-923013	19950608
	EP 1391461	A1	20040225	EP 2003-18280	19950608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
IE	PRAI US 1994-255276	A	19940608		
	EP 1995-923013	A3	19950608		
	WO 1995-US7314	W	19950608		
OS	MARPAT 124:261732				
GI					



AB ZNHY [Y = CRR1(CH2)nCO2R2; R = C:NNHCONH2, COR3, etc.; R1 = H or  
 deuterium; R2 = OH, alkoxy, NHOH, etc.; R3 = H, pyrazolyloxymethyl,  
 benzoyloxymethyl, etc.; Z = azabicycloalkylcarbonyl, etc.; n = 1 or 2] were  
 prepared Thus, pyridazinodiazepinecarboxylate I (R5 = PhCH2O2C, R6 = H)

was amidated and the deprotected product amidated to give I [R5 = 4-(Me2N)C6H4CO, R6 = Q]. Selected I had IC50 of <10µM against release of interleukin-1β from human monocytes in vitro.

IT 174799-03-2P 174799-04-3P 174799-05-4P  
174799-06-5P 174799-07-6P 174799-08-7P  
174799-09-8P 174799-10-1P 174799-11-2P  
174799-12-3P 174799-13-4P 174799-14-5P  
174799-15-6P 174799-16-7P 174799-17-8P  
174799-18-9P 174799-19-0P 174799-20-3P  
174799-21-4P 174799-22-5P 174799-23-6P  
174799-24-7P 174799-25-8P 174799-26-9P  
174799-27-0P 174799-28-1P 174799-29-2P  
174799-30-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-(oxodiazabicycloalkylcarbonyl)aspartates as interleukin-1β converting enzyme inhibitors)

RN 174799-03-2 CAPLUS

CN Pentanoic acid, 5-[[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-04-3 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-05-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(1S,9S)-octahydro-6,10-dioxo-9-[[ (phenylmethoxy) carbonyl] amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 174799-06-5 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-6,10-dioxo-9-[[ (phenylmethoxy) carbonyl] amin o]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-07-6 CAPLUS

CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[ (phenylmethoxy) carbonyl] amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-08-7 CAPLUS

CN Pentanoic acid, 3-[[[octahydro-6,10-dioxo-9-[[ (phenylmethoxy) carbonyl] amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-[[1-(2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 174799-09-8 CAPLUS

CN Pentanoic acid, 3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, [1S-

[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-10-1 CAPLUS

CN Pentanoic acid, 3-[[[9-[[4-[(carboxymethyl)thio]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-11-2 CAPLUS

CN Pentanoic acid, 3-[[[9-[[4-[(2-carboxyethyl)thio]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—CF<sub>3</sub>

RN 174799-12-3 CAPLUS  
 CN Pentanoic acid, 5-[[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-9-[[ (2-methylpropoxy) carbonyl] amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-13-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-14-5 CAPLUS

CN Benzenepropanoic acid, 4-[[[4-[[[1-(carboxymethyl)-3-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, [4S-[4α(R\*),7α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-15-6 CAPLUS


CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-(4-morpholinylmethyl)benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

Cl



PAGE 1-B

RN 174799-16-7 CAPLUS


CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester,

[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

Cl



PAGE 1-B




RN 174799-17-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-9-[[4-[(2-methyl-1H-

imidazol-1-yl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-2-oxobutyl ester,

[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 174799-18-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 3-[[[9-[(1H-benzimidazol-5-ylcarbonyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-

yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester, [1S-  
[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-19-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 3-[[[9-[(1H-benzotriazol-5-yl)carbonyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-carboxy-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 174799-20-3 CAPLUS

CN 1H-Benzotriazole-1-carboxylic acid, 5-[[[4-[[[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, 1-ethyl ester, [4S-[4 $\alpha$ (R\*),7 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—OEt

RN 174799-21-4 CAPLUS

CN 1H-Benzimidazole-1-carboxylic acid, 5-[[[4-[[[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, 1-ethyl ester, [4S-[4 $\alpha$ (R\*),7 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OEt

RN 174799-22-5 CAPLUS

CN Benzenebutanoic acid, 4-[[[4-[[[1-(carboxymethyl)-3-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-2-oxopropyl]amino]carbonyl]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-7-yl]amino]carbonyl]-, [4S-[4 $\alpha$ (R\*),7 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

—CF<sub>3</sub>

RN 174799-23-6 CAPLUS

CN Butanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 174799-24-7 CAPLUS

CN Butanoic acid, 3-[[[9-[[4-(carboxymethoxy)benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-25-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[octahydro-10-oxo-9-  
[[ (phenylmethoxy) carbonyl] amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-  
yl]carbonyl]amino]-2-oxobutyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 174799-26-9 CAPLUS

CN Pentanoic acid, 5-[[1-(5-chloro-2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[ (phenylmethoxy) carbonyl] amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-27-0 CAPLUS

CN Pentanoic acid, 3-[[[9-[[4-  
[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-  
pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-  
[[1-(2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-,  
[1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-28-1 CAPLUS

CN Butanoic acid, 3-[[[1S,9S)-9-[(2-fluorobenzoyl)amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-29-2 CAPLUS

CN Butanoic acid, 3-[[[octahydro-6,10-dioxo-9-[(2-pyridinylcarbonyl)amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-30-5 CAPLUS

CN Butanoic acid, 3-[[[octahydro-9-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, [1S-[1α(R\*),9α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174799-33-8P 174799-34-9P 174799-35-0P  
174799-36-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)

(preparation of N-(oxodiazabicycloalkylcarbonyl)aspartates as  
interleukin-1 $\beta$  converting enzyme inhibitors)

RN 174799-33-8 CAPLUS

CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[octahydro-6,10-dioxo-9-[[phenylmethoxy]carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-34-9 CAPLUS

CN Pentanoic acid, 3-[[[9-amino-octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-4-oxo-, 1,1-dimethylethyl ester, monohydrochloride, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174799-35-0 CAPLUS

CN Pentanoic acid, 5-[[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-3-[[[9-[[4-[(dimethylamino)methyl]benzoyl]amino]octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 174799-36-1 CAPLUS


CN Hexanoic acid, 6-[(aminocarbonyl)hydrazono]-3-[[[octahydro-6,10-dioxo-9-[[[(phenylmethoxy)carbonyl]amino]-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, [1S-[1 $\alpha$ (3R\*),9 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




Beilstein Records (BRN): 8372336  
Autonom Name (AUN): 3-<(9-benzoylamino-6,10-dioxo-octahydro-  
pyridazino<1,2-a><1,2>diazepine-1-  
carbonyl)-amino>-N-methoxy-N-methyl-  
succinamic acid tert-butyl ester  
Molec. Formula (MF): C27 H37 N5 O8  
Molecular Weight (MW): 559.62  
Lawson Number (LN): 29859, 10581, 3625, 3487, 318, 289  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 7107718  
Tautomer ID (TAUTID): 7902041  
Entry Date (DED): 2000/03/08  
Update Date (DUPD): 2000/03/08



Reference(s):

1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R.,  
Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592;  
BABS-6189425


Beilstein Records (BRN): 8368830  
Autonom Name (AUN): 3-[(9-benzoylamino-6,10-dioxo-octahydro-  
pyridazino<1,2-a><1,2>diazepine-1-  
carbonyl)-amino]-4-oxo-butyl ester  
tert-butyl ester  
Molec. Formula (MF): C<sub>25</sub> H<sub>32</sub> N<sub>4</sub> O<sub>7</sub>  
Molecular Weight (MW): 500.55  
Lawson Number (LN): 29859, 10581, 3614, 318  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 7104430  
Tautomer ID (TAUTID): 7901073  
Entry Date (DED): 2000/03/08  
Update Date (DUPD): 2000/03/08



Reference(s):


1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R.,  
Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592;  
BABS-6189425

Beilstein Records (BRN): 7791359  
Molec. Formula (MF): C34 H32 Cl F3 N6 O10 S  
Molecular Weight (MW): 809.17  
Lawson Number (LN): 29859, 28329, 16436, 11689, 3616, 1774  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6647679  
Tautomer ID (TAUTID): 7373455  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




L7 ANSWER 4 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN


Beilstein Records (BRN): 7791282  
Molec. Formula (MF): C36 H36 Cl F3 N6 O10  
Molecular Weight (MW): 805.16  
Lawson Number (LN): 29859, 28329, 16436, 11187, 3616  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6648049  
Tautomer ID (TAUTID): 7373231  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




Beilstein Records (BRN): 7791183  
 Molec. Formula (MF): C35 H37 Cl F3 N7 O8  
 Molecular Weight (MW): 776.17  
 Lawson Number (LN): 29859, 28329, 16436, 16047, 3616, 2817  
 File Segment (FS): Stereo compound  
 Compound Type (CTYPE): heterocyclic  
 Constitution ID (CONSID): 6646975  
 Tautomer ID (TAUTID): 7372503  
 Beilstein Citation (BSO): 6-25  
 Entry Date (DED): 1998/03/03  
 Update Date (DUPD): 1998/03/03




Beilstein Records (BRN):	7791095
Molec. Formula (MF):	C36 H42 Cl2 N6 O9
Molecular Weight (MW):	773.67
Lawson Number (LN):	29859, 28000, 16047, 10584, 3616, 2817
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6647412
Tautomer ID (TAUTID):	7373666
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03




Beilstein Records (BRN): 7791046  
Molec. Formula (MF): C33 H32 Cl F3 N6 O9  
Molecular Weight (MW): 749.10  
Lawson Number (LN): 29859, 28329, 16436, 5228, 3616, 1762  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6646554  
Tautomer ID (TAUTID): 7370899  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




Beilstein Records (BRN): 7790974  
Molec. Formula (MF): C35 H39 Cl2 N5 O10  
Molecular Weight (MW): 760.63  
Lawson Number (LN): 30824, 29859, 16047, 10584, 3616  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6647328  
Tautomer ID (TAUTID): 7373590  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




Beilstein Records (BRN): 7790944  
Molec. Formula (MF): C35 H36 Cl2 N6 O9  
Molecular Weight (MW): 755.61  
Lawson Number (LN): 29859, 28030, 16047, 10584, 3616  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6646784  
Tautomer ID (TAUTID): 7374141  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




Beilstein Records (BRN): 7790905  
Molec. Formula (MF): C33 H33 F3 N6 O9  
Molecular Weight (MW): 714.65  
Lawson Number (LN): 29859, 28329, 16435, 5228, 3616, 1762  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6645676  
Tautomer ID (TAUTID): 7370682  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




Beilstein Records (BRN): 7790071  
Molec. Formula (MF): C31 H32 Cl2 N4 O10  
Molecular Weight (MW): 691.52  
Lawson Number (LN): 29859, 10584, 5228, 3616, 1762  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6644745  
Tautomer ID (TAUTID): 7371873  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03



Beilstein Records (BRN): 7787164  
Molec. Formula (MF): C23 H26 N4 O10  
Molecular Weight (MW): 518.48  
Lawson Number (LN): 29859, 11694, 3614, 1771  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6637771  
Tautomer ID (TAUTID): 7371033  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




Beilstein Records (BRN): 7785794  
Molec. Formula (MF): C22 H26 N4 O8  
Molecular Weight (MW): 474.47  
Lawson Number (LN): 29859, 5228, 3614, 1762  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6632614  
Tautomer ID (TAUTID): 7365353  
Beilstein Citation (BSO): 6-25  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




L7 ANSWER 14 OF 15 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7785257
Molec. Formula (MF):	C21 H23 F N4 O7
Molecular Weight (MW):	462.43
Lawson Number (LN):	29859, 10582, 3614
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6633495
Tautomer ID (TAUTID):	7367962
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Beilstein Records (BRN):	7784055
Chemical Name (CN):	PD 194035
Molec. Formula (MF):	C21 H24 N4 O7
Molecular Weight (MW):	444.44
Lawson Number (LN):	29859, 10581, 3614
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6629728
Tautomer ID (TAUTID):	7367706
Beilstein Citation (BSO):	6-25
Entry Date (DED):	1998/03/03
Update Date (DUPD):	2000/03/07



Reference(s):

1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R.,  
Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592;  
BABS-6189425


Reference(s):

1. Chen, M. H.; Goel, O. P.; Hyun, J.-W.; Magano, J.; Rubin, J. R.,  
Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 9(11), <1999>, 1587 - 1592;  
BABS-6189425

L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2004 ACS on STN  
 AN 126:8707 MARPAT Full-text  
 TI Preparation of beta-sheet mimetics of peptides or proteins as inhibitors  
 of biologically active peptides or proteins  
 IN Kahn, Michael  
 PA Molecumetics Ltd., USA  
 SO PCT Int. Appl., 158 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9630035	A1	19961003	WO 1996-US4044	19960325
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2215695	AA	19961003	CA 1996-2215695	19960325
	CA 2215695	C	20030916		
	CA 2215720	AA	19961003	CA 1996-2215720	19960325
	AU 9653714	A1	19961016	AU 1996-53714	19960325
	AU 712581	B2	19991111		
	EP 817642	A1	19980114	EP 1996-910547	19960325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 10508034	T2	19980804	JP 1996-529567	19960325
	JP 2000319295	A2	20001121	JP 2000-79170	19960325
	ES 2161354	T3	20011201	ES 1996-910566	19960325
	US 6020331	A	20000201	US 1998-9386	19980120
	US 6245764	B1	20010612	US 1998-9665	19980120
	US 6586426	B1	20030701	US 1999-443055	19991118
	US 6699869	B1	20040302	US 2000-561107	20000428
	US 2003191109	A1	20031009	US 2001-8770	20011025
PRAI	US 1995-410518		19950324		
	US 1995-549006		19951027		
	JP 1996-529594		19960325		
	US 1996-624690		19960325		
	US 1996-624695		19960325		
	WO 1996-US4044		19960325		
	US 1996-725073		19961002		
	US 1998-4968		19980109		
	US 1998-9386		19980120		
	US 1998-9665		19980120		

GI



AB There are disclosed  $\beta$ -sheet mimetics [I; R1 - R3 = amino acid side chain moiety or its derivative; A = CO, (CH<sub>2</sub>)<sub>1-4</sub>, (CH<sub>2</sub>)<sub>1-2</sub>-O, (CH<sub>2</sub>)<sub>1-2</sub>-S; B = N, CH; C = CO, (CH<sub>2</sub>)<sub>1-3</sub>, O, S, O(CH<sub>2</sub>)<sub>1-2</sub>, S(CH<sub>2</sub>)<sub>1-2</sub>; Y, Z = the remainder of the mol.; or any 2 adjacent CH groups of the bicyclic ring may form a double bond] and methods relating to the same for imparting or stabilizing the  $\beta$ -sheet structure of a peptide, protein or mol. In one aspect, the  $\beta$ -sheet mimetics are covalently attached at the end or within the length of the peptide or protein. The  $\beta$ -sheet mimetics have utility as inhibitors of one or more of proteases, kinases, CAAX motif (Ras prenylation of the Cys within its C-terminal CAAX sequence by farnesyl transferase, wherein "A" is defined as an amino acid with a hydrophobic side chain and "X" is another amino acid), peptides binding to SH2 domains, and MHC-I and/or MHC-II (major histocompatibility complex class I and class II) presentation of peptides to T cell receptors in warm-blooded animals. Thus, azabicyclo[4.3.0]nonane derivative (II; R = Boc, R<sub>4</sub> = OH) (preparation given) was condensed with benzothiazolylargininol derivative (H-Q.CF<sub>3</sub>CO<sub>2</sub>H; R<sub>5</sub> = Q1, Z = CHOH) using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HOBT, and (Me<sub>2</sub>CH)<sub>2</sub>NEt in THF to give arginol derivative II (R = Boc, R<sub>4</sub> = Q, R<sub>5</sub> = Q1 Z = CHOH), which was oxidized by Dess-Martin periodinane in CH<sub>2</sub>Cl<sub>2</sub> to arginine derivative II (R = Boc, R<sub>4</sub> = Q, R<sub>5</sub> = Q1 Z = CO) and deprotected 95% aqueous CF<sub>3</sub>CO<sub>2</sub>H and thioanisole at room temperature for 20 h to give, after HPLC purification, the  $\beta$ -sheet mimetic II (R = H, R<sub>4</sub> = Q, R<sub>5</sub> = H, Z = CO). The latter compound in vitro inhibited various serine proteases such as thrombin, factor VII, factor X, factor XI, urokinase, thrombin-thrombomodulin complex, activated protein C, plasmin, tissue plasminogen activator, trypsin, and tryptase, e.g. with K<sub>i</sub> of 8.50 + 10<sup>-11</sup> M for thrombin.

#### MSTR 1




G2 = N  
G7 = 80




G8 = (1-4) CH<sub>2</sub>  
G12 = (1-3) 24




G15 = 7-15 2-11



G29 = 162




G31 = 157



MPL: claim 1  
NTE: substitution is restricted  
NTE: additional double bond formation possible  
STE: 443 - D

=> d l1; d his; log y  
 L1 HAS NO ANSWERS  
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 15:59:35 ON 04 MAR 2004)

FILE 'REGISTRY' ENTERED AT 15:59:43 ON 04 MAR 2004  
 L1 STRUCTURE UPLOADED  
 L2 16 S L1  
 L3 344 S L1 FUL

FILE 'CAPLUS' ENTERED AT 16:00:46 ON 04 MAR 2004  
 L4 12 S L3

FILE 'BEILSTEIN' ENTERED AT 16:02:07 ON 04 MAR 2004  
 L5 1 S L1  
 L6 15 S L1 FUL  
 L7 15 S L6 NOT L4

FILE 'MARPAT' ENTERED AT 16:03:14 ON 04 MAR 2004  
 L8 1 S L1  
 L9 10 S L1 FUL  
 L10 1 S L9 NOT L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	114.71	519.91
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.66	-8.98

STN INTERNATIONAL LOGOFF AT 16:05:04 ON 04 MAR 2004

*electes compound*

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:136764 CAPLUS Full-text

DN 130:196957

TI Preparation of bicyclic peptide derivatives as interleukin-1 $\beta$   
converting enzyme inhibitors

IN Batchelor, Mark James; Bebbington, David; Bemis, Guy W.; Fridman, Wolf  
Herman; Gillespie, Roger John; Golec, Julian M. C.; Lauffer, David J.;  
Livingston, David J.; Matharu, Saroop Singh; Mullican, Michael D.;  
Murcko, Mark A.; Murdoch, Robert; Zelle, Robert E.

PA Vertex Pharmaceuticals Incorporated, USA

SO U.S., 189 pp., Cont.-in-part of U.S. Ser. No. 575,641.

CODEN: USXXAM


DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5874424	A	19990223	US 1996-598332	19960208
	US 6008217	A	19991228	US 1995-575641	19951220
	US 6204261	B1	20010320	US 1996-761483	19961206
	IN 182290	A	19990306	IN 1996-CA2188	19961218
	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9610798	A	19970707	ZA 1996-10798	19961220
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9612258	A	19990713	BR 1996-12258	19961220
	CN 1229412	A	19990922	CN 1996-199828	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	JP 2003137896	A2	20030514	JP 2002-306094	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	US 6258948	B1	20010710	US 1999-400639	19990921
	US 6423840	B1	20020723	US 2001-773477	20010131
	AU 756253	B2	20030109	AU 2001-76122	20010928
	US 2003225269	A1	20031204	US 2002-58522	20020128
PRAI	US 1995-575641	A2	19951220		
	US 1996-598332	A2	19960208		
	US 1996-712878	A2	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	JP 1997-523098	A3	19961220		
	WO 1996-US20843	W	19961220		
	US 1999-400639	A3	19990921		
	US 2001-773477	A3	20010131		

OS MARPAT 130:196957  
GI



I



II

AB Title compds. I [ $m = 1-2$ ;  $R_3 = \text{CN, CHO, COCH}_2\text{-T1-R11, COCH}_2\text{F, C:NOR}_9, \text{COAr}_2$ ;  $R_5 = \text{COR}_{10}, \text{CO}_2\text{R}_9, \text{CONR}_{102}, \text{SO}_2\text{R}_9, \text{SO}_2\text{NHR}_{10}, \text{COCH}_2\text{OR}_9, \text{COCOR}_{10}, \text{R}_9, \text{H, COCO}_2\text{R}_{10}, \text{COCONR}_9\text{R}_{10}$ ;  $Y = \text{O, H}_2$ ;  $\text{T1} = \text{O, S, S(O), SO}_2$ ;  $\text{R}_9 = \text{Ar}_3$ , (un)branched C1-6 alkyl optionally unsatd. and optionally substituted with  $\text{Ar}_3$ ;  $\text{R}_{10} = \text{H, Ar}_3$ , C3-6 cycloalkyl, any group  $\text{R}_9$ ;  $\text{R}_{11} = \text{Ar}_4$ ,  $(\text{CH}_2)_{1-3}\text{Ar}_4$ ,  $\text{H, COAr}_4$ ;  $\text{R}_{15} = \text{OH, OAr}_3, \text{NHOH}$ , (un)branched C1-6 alkoxy optionally unsatd. and optionally substituted with  $\text{Ar}_3$ ,  $\text{CONH}_2$ ,  $\text{OR}_5$ ,  $\text{OH, OR}_9, \text{CO}_2\text{H}$ ;  $\text{Ar}_2 =$  (un)substituted 2-oxazolyl, 2-benzoxazolyl, 2-thiazolyl, 2-benzothiazolyl;  $\text{Ar}_3, \text{Ar}_4 =$  optionally substituted, nitrogen-containing heteroarom. or heterocyclic group containing 1-3 rings] were prepared as inhibitors of interleukin-1 $\beta$  converting enzyme. Thus, bicyclic peptide derivative II was prepared and shown to have  $K_i = 13 \text{ nM}$  in a UV-visible assay and  $\text{IC}_{50} = 11000 \text{ nM}$  in a peripheral blood mononuclear cell (PBMC) assay.


IT 192755-30-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of bicyclic peptide derivs. as interleukin-1 $\beta$  converting enzyme inhibitors)

RN 192755-30-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:502830 CAPLUS Full-text  
 DN 127:122000  
 TI Inhibitors of interleukin-1 $\beta$  converting enzyme  
 IN Batchelor, Mark J.; Bebbington, David; Bemis, Guy W.; Fridman, Wolf  
 Herman; Gillespie, Roger J.; Golec, Julian M. C.; Gu, Yong; Lauffer,  
 David J.; Livingston, David J.; Matharu, Saroop S.; Mullican, Michael  
 D.; Murcko, Mark A.; Murdoch, Robert; Nyce, Philip L.; Robidoux, Andrea  
 L. C.; et al.  
 PA USA  
 SO PCT Int. Appl., 946 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9722619	A2	19970626	WO 1996-US20843	19961220
	WO 9722619	A3	19971016		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6008217	A	19991228	US 1995-575641	19951220
	US 5874424	A	19990223	US 1996-598332	19960208
	US 5985863	A	19991116	US 1996-712878	19960912
	US 6204261	B1	20010320	US 1996-761483	19961206
	AU 9715222	A1	19970714	AU 1997-15222	19961220
	AU 735075	B2	20010628		
	EP 869967	A2	19981014	EP 1996-945318	19961220
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9612258	A	19990713	BR 1996-12258	19961220
	NZ 326610	A	20000825	NZ 1996-326610	19961220
	JP 2002507961	T2	20020312	JP 1997-523098	19961220
	NO 9802597	A	19980812	NO 1998-2597	19980605
	AU 756253	B2	20030109	AU 2001-76122	20010928
PRAI	US 1995-575641	A	19951220		
	US 1996-598332	A	19960208		
	US 1996-712878	A	19960912		
	US 1996-31495P	P	19961126		
	US 1996-761483	A	19961206		
	AU 1997-15222	A3	19961220		
	WO 1996-US20843	W	19961220		
OS	MARPAT 127:122000				
AB	Compds. R(CH <sub>2</sub> ) <sub>n</sub> CH(NHR <sub>1</sub> )(CR <sub>22</sub> )mR <sub>3</sub> [R = NC, R <sub>4</sub> CH:CH, R <sub>4</sub> ON:CH, R <sub>4</sub> CR <sub>22</sub> , etc. where R <sub>2</sub> is independently selected from H, OH, F and R <sub>4</sub> is (un)substituted alkyl; R <sub>1</sub> = R <sub>5</sub> NHCHR <sub>6</sub> CONR <sub>7</sub> CHR <sub>8</sub> CO, where CHR <sub>6</sub> CONR <sub>7</sub> is a 2-oxoazepine ring substituted by benzo, pyrido, thieno, or related rings at the 6,7-position and optionally may have O, NH, S, SO, or SO <sub>2</sub> at the 5-position, R <sub>5</sub> and R <sub>8</sub> are H, cyclic group, etc.; R <sub>3</sub> = OH, COCOCO <sub>2</sub> H, CO <sub>2</sub> H, or any bioisosteric replacement for CO <sub>2</sub> H; m = 0, 1, 2; n = 0, 1]				

were prepared as inhibitors of interleukin-1 $\beta$  converting enzyme. Thus, [1S,9S(2RS,3S)]-9- benzoylamino-6,10-dioxo-1,2,3,4,7,8,9,10-octahydro-N-(2-benzyloxy-5- oxotetrahydrofuran-3-yl)-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamide was prepared and shown to have IC50 values of 900 and 600 nM, resp., in the peripheral blood mononuclear cell (PBMC) and whole human blood assays.


IT 192755-30-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 192755-30-9 CAPLUS

CN Pentanoic acid, 3-[[[(1S,9S)-9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-yl]carbonyl]amino]-4-oxo-5-(3-pyridinyloxy)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d l1; d his; log y  
L1 HAS NO ANSWERS  
L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 10:10:56 ON 04 MAR 2004)

FILE 'REGISTRY' ENTERED AT 10:11:05 ON 04 MAR 2004  
L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 1 S L1 FUL



FILE 'CAPLUS' ENTERED AT 10:11:55 ON 04 MAR 2004  
L4 2 S L3

FILE 'BEILSTEIN' ENTERED AT 10:12:27 ON 04 MAR 2004  
L5 0 S L1 FUL

FILE 'MARPAT' ENTERED AT 10:12:50 ON 04 MAR 2004  
L6 0 S L1  
L7 0 S L1 FUL

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	109.42	275.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.39

STN INTERNATIONAL LOGOFF AT 10:13:14 ON 04 MAR 2004



chain nodes :

12 13 14 15 16 17 18 20 21 22 23 25 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 19 24 31 32 33 34 35 36 37 38 39 40

chain bonds :

1-20 2-22 5-21 11-12 12-13 12-15 13-14 14-16 14-26 16-17 16-30 17-18 18-19  
22-23 23-24 23-25 26-27 27-28 27-29

ring bonds :

1-2 1-7 2-3 3-4 4-5 5-6 6-7 6-8 7-11 8-9 9-10 10-11 19-36 19-40 24-31 24-35  
31-32 32-33 33-34 34-35 36-37 37-38 38-39 39-40

exact/norm bonds :

1-2 1-7 1-20 2-3 2-22 3-4 4-5 5-6 5-21 6-7 6-8 7-11 8-9 9-10 10-11 12-13  
12-15 13-14 16-30 17-18 18-19 22-23 23-25

exact bonds :

11-12 14-16 14-26 16-17 23-24 26-27

normalized bonds :

19-36 19-40 24-31 24-35 27-28 27-29 31-32 32-33 33-34 34-35 36-37 37-38 38-39  
39-40

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 20:CLASS  
21:CLASS 22:CLASS 23:CLASS 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS  
30:CLASS 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom  
40:Atom